Acadia Healthcare Raises Full-Year EPS, EBITDA Forecasts After Strong Q1 Beat
ACHC has more than doubled off its 52-week low of $11.43.
Summary
Acadia Healthcare reported robust first-quarter results, with revenue of $828.80 million and adjusted EBITDA of $144.20 million, both surpassing analyst expectations. Following this strong performance, the company raised its full-year 2026 adjusted EPS guidance to $1.35-$1.60 (from $1.30-$1.55) and adjusted EBITDA guidance to $580 million-$615 million. This positive operational update, driven by higher patient volumes and increased revenue per patient day, provides a strong counterpoint to the recent 8-K filing regarding a CFO change. The raised outlook signals improved profitability and operational momentum, which is a significant positive catalyst for the stock. Traders will be watching for sustained volume growth and the impact of capacity expansion on future results.
At the time of this announcement, ACHC was trading at $26.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $11.43 to $28.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.